News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
292,705 Results
Type
Article (15921)
Company Profile (62)
Press Release (276722)
Multimedia
Podcasts (134)
Webinars (14)
Section
Business (104195)
Career Advice (505)
Deals (15969)
Drug Delivery (144)
Drug Development (38277)
Employer Resources (51)
FDA (6894)
Job Trends (6584)
News (155973)
Policy (14765)
Tag
2026 Best Places to Work (1)
2027 BioCapital Standard (1)
2027 BioMidwest Digital (1)
2027 BioMidwest Standard (2)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (2)
2027 Genetown Premier (1)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (7)
40 Under 40 (2)
Academia (506)
Accelerated approval (35)
ADA (24)
Adcomms (13)
Allergies (114)
Alliances (23934)
ALS (91)
Alzheimer's disease (624)
Antibody-drug conjugate (ADC) (260)
Approvals (7339)
Artificial intelligence (398)
ASCO (120)
Autoimmune disease (122)
Automation (27)
Bankruptcy (160)
Belgium (7)
Best Places to Work (4615)
BIO (28)
Biologics (42)
BIOSECURE Act (10)
Biosimilars (200)
BioSpace Insights (78)
Biotechnology (30)
Bispecific (10)
Bladder cancer (62)
Brain cancer (47)
Breast cancer (276)
Cancer (2217)
Cardiovascular disease (320)
Career advice (456)
Career pathing (16)
CAR-T (86)
CDC (15)
CDMO (116)
Celiac Disease (1)
Cell therapy (258)
Cervical cancer (23)
Clinical research (34414)
Collaboration (1203)
Commercialization (36)
Company closure (3)
Compensation (487)
Complete response letters (62)
COVID-19 (836)
CRISPR (67)
CRO (1)
C-suite (887)
Cystic fibrosis (71)
Data (3450)
Decentralized trials (3)
Denatured (22)
Depression (74)
Dermatology (43)
Diabetes (347)
Diagnostics (1686)
Digital health (25)
Diversity (4)
Diversity, equity & inclusion (14)
Drug discovery (226)
Drug pricing (183)
Drug shortages (33)
Duchenne muscular dystrophy (122)
Earnings (35880)
Editorial (39)
Employer branding (4)
Employer resources (48)
ESMO (126)
Events (42061)
Executive appointments (726)
Eye disease (3)
FDA (8814)
Fibrodysplasia Ossificans Progressiva (10)
Fragile X (4)
Friedreich's ataxia (3)
Frontotemporal dementia (7)
Funding (752)
Gene editing (108)
Generative AI (51)
Gene therapy (264)
GLP-1 (990)
Government (1622)
Grass and pollen (4)
Guidances (189)
Healthcare (4117)
Hematology (75)
HIV (25)
Huntington's disease (17)
Idiopathic pulmonary fibrosis (4)
IgA nephropathy (72)
Immunology and inflammation (118)
Immuno-oncology (49)
Indications (139)
Infectious disease (956)
Inflammatory bowel disease (99)
Inflation Reduction Act (12)
Influenza (32)
Intellectual property (168)
Interviews (63)
IPO (6177)
IRA (44)
Job creations (2134)
Job search strategy (401)
JPM (40)
Kidney cancer (18)
Kidney disease (56)
Labor market (52)
Layoffs (259)
Leadership (17)
Legal (3571)
Licensing (73)
Liver cancer (29)
Longevity (18)
Lung cancer (317)
Lung diease (5)
Lymphoma (190)
Machine learning (19)
Management (19)
Manufacturing (842)
Marketing (22)
MASH (128)
Medical affairs (3)
Medical device (1682)
Medtech (1713)
Mergers & acquisitions (10468)
Metabolic disorders (1207)
Middle East (1)
mRNA (95)
Multiple sclerosis (76)
Multispecific (1)
NASH (17)
Netherlands (4)
Neurodegenerative disease (165)
Neuropsychiatric disorders (62)
Neuroscience (1317)
Neurotech (2)
NextGen: Class of 2026 (1778)
Non-profit (703)
Now hiring (56)
Obesity (725)
Opinion (168)
Ovarian cancer (89)
Pain (169)
Pancreatic cancer (98)
Parkinson's disease (134)
Partnered (16)
Patents (348)
Patient advocacy (1)
Patient recruitment (261)
Patient selection (32)
Peanut (16)
People (31371)
Peptides (17)
Pharmaceutical (34)
Pharmacy benefit managers (23)
Phase 1 (8878)
Phase 2 (14475)
Phase 3 (13190)
Pipeline (5379)
Policy (207)
Postmarket research (1444)
Preclinical (3577)
Press Release (25)
Prostate cancer (141)
Psychedelics (37)
Radioligand (1)
Radiopharmaceuticals (197)
Rare diseases (649)
Real estate (2777)
Recruiting (19)
Regenerative medicine (6)
Regulatory (12525)
Reports (22)
Research institute (623)
Resumes & cover letters (64)
Rett syndrome (19)
RNA editing (15)
RSV (28)
Saudi Arabia (1)
Schizophrenia (106)
Series A (165)
Series B (90)
Service/supplier (1)
Sickle cell disease (78)
Special edition (14)
Spinal muscular atrophy (97)
Sponsored (14)
Startups (1730)
State (2)
Stem cells (2)
Stomach cancer (8)
Substance use disorders (10)
Supply chain (97)
Switzerland (12)
Tariffs (80)
The Weekly (109)
Vaccines (337)
Venture capital (69)
Weight loss (543)
Wet AMD (3)
Women's health (74)
Worklife (5)
Date
Today (45)
Last 7 days (371)
Last 30 days (1194)
Last 365 days (11525)
2026 (10088)
2025 (11531)
2024 (13223)
2023 (14844)
2022 (20218)
2021 (20771)
2020 (19758)
2019 (15726)
2018 (12440)
2017 (14433)
2016 (13568)
2015 (15919)
2014 (12769)
2013 (10871)
2012 (11719)
2011 (12292)
2010 (11179)
Location
Africa (340)
Alabama (27)
Alaska (4)
Arizona (110)
Arkansas (5)
Asia (22021)
Australia (2926)
California (4919)
Canada (2156)
China (983)
Colorado (214)
Connecticut (211)
Delaware (208)
Europe (45013)
Florida (933)
Georgia (94)
Hawaii (2)
Idaho (12)
Illinois (564)
India (108)
Indiana (390)
Iowa (5)
Japan (471)
Kansas (90)
Kentucky (24)
Louisiana (12)
Maine (2)
Maryland (603)
Massachusetts (3945)
Michigan (77)
Minnesota (257)
Mississippi (2)
Missouri (42)
Montana (9)
Nebraska (12)
Nevada (27)
New Hampshire (12)
New Jersey (2243)
New Mexico (7)
New York (1374)
North Carolina (890)
North Dakota (2)
Northern California (2369)
Ohio (122)
Oklahoma (8)
Oregon (18)
Pennsylvania (1019)
Puerto Rico (38)
Rhode Island (22)
South America (593)
South Carolina (16)
Southern California (2188)
Tennessee (94)
Texas (693)
United States (19344)
Utah (78)
Vermont (1)
Virginia (265)
Washington D.C. (43)
Washington State (377)
West Virginia (1)
Wisconsin (78)
Wyoming (2)
292,705 Results for "novo nordisk pharmaceuticals puerto rico".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
C-suite
Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand
Analysts tentatively welcomed Novo’s new corporate rebrand—so long as it comes with a larger change to the company’s overall business strategy.
September 14, 2026
·
3 min read
·
Annalee Armstrong
Weight loss
Novo Nordisk starts trialing lower maintenance doses of oral Wegovy
The Phase 3 study is evaluating two doses of Novo’s Wegovy pill in people with obesity or overweight in combination with a reduced-calorie diet and increased physical activity.
August 21, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
Novo Nordisk A/S - share repurchase programme - November 3, 2026
November 3, 2026
·
2 min read
Sickle cell disease
Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset
Agios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the indication.
July 21, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
Novo Nordisk A/S - share repurchase programme - October 26, 2026
October 26, 2026
·
2 min read
Press Releases
Novo Nordisk A/S - share repurchase programme - October 19, 2026
October 19, 2026
·
2 min read
Press Releases
Novo Nordisk A/S - share repurchase programme - October 12, 2026
October 12, 2026
·
2 min read
Press Releases
Novo Nordisk A/S – Share repurchase programme - October 5, 2026
October 5, 2026
·
2 min read
cardiovascular disease
Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’
After the failure of Novo Nordisk’s IL-6 inhibitor ziltivekimab sent waves through the industry, the company has terminated two other studies of the asset, bringing the total number of high-profile cardiovascular flops to six over nine weeks.
September 8, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
Novo Nordisk A/S - share repurchase programme - September 28, 2026
September 28, 2026
·
2 min read
1 of 29,271
Next